Lay Blame...


anonymous

Guest
You could argue that Avinger should have been a big success by now for a number of reasons: good pedigree; disruptive technology; solid clinical results. And yet, it just had another shake-up and some gut-wrenching personnel cuts. They literally can't even give away their technology.

So let's lay some blame. Where did things go south? Sales and marketing? Engineering? Executive leadership? All three?

Help others, by sharing the things you learned from Avinger's mistakes.
 




We are striving and will come bounce back after we get the $40m in additional funding. It's in the works now and Santillo is orchestrating it.

Good point. Because if there's one name that reverberates throughout the halls of medical device history, it's "Santillo." That guy wrote the book on success. Hell he's so good, he wrote the book on writing books.
 













Write your reply...